The efficacy of behavioural activation treatment for co-occurring depression and substance use disorder (the activate study): a randomized controlled trial

Joanne Ross1,2*, Maree Teesson1,2, Carl Lejuez3, Katherine Mills1,2, Sharlene Kaye1,2, Kathleen Brady4, Glenys Dore5, Katrina Prior1,2, Xanthe Larkin1,2, Joanne Cassar1,2, Philippa Ewer1,2, Sonja Memedovic1,2, Ivana Kihas1,2 and Sarah Louise Masters1,2

Abstract

Background: Epidemiological studies suggest that compared with the general population, mood disorders are up to 4.7 times more prevalent in substance dependent samples. Comorbid substance use disorder (SUD) and depression has been associated with a more severe and protracted illness course and poorer treatment outcomes. Despite this, the development and assessment of behavioural interventions for treating depression among individuals with SUDs have received little empirical attention. Behavioural Activation Treatment for Depression (BATD-R) is an empirically supported treatment for depression that has shown some efficacy among substance users. This paper describes the study protocol of a parallel, single blind, randomised controlled trial to determine the efficacy and feasibility of a modified version of the BATD-R (Activate) in reducing symptoms of depression and substance dependence among individuals in residential rehabilitation (RR) and opioid substitution therapy (OST).

Methods/design: A sample of approximately 200 individuals with depressive symptomatology in treatment for SUD will be recruited from RR and OST services in New South Wales, Australia. Dynamic random allocation following minimisation methodology will be used to assign participants to one of two groups. The control group will receive treatment as usual (TAU), which will be the model of care provided in accordance with standard practice at participating RR and OST services. The intervention group will receive Activate, comprising 10 individual 60-min therapy sessions with a psychologist employed on the research team, in addition to TAU. Data collection will occur at baseline (pre-intervention), and 3-months and 12-months post baseline.

Discussion: The association between depression and substance dependence has been well documented, yet practical and effective treatments are scarce. The findings of the present study will contribute significantly to understanding the types of programs that are effective in treating this comorbidity.

Trial registration: This trial is registered with the Australian and New Zealand Clinical Trials registry, ACTRN12613000876796. Registered on 7 August, 2013.

Keywords: Activate, BATD-R, Behavioural activation, Depression, Substance use disorder, Randomised controlled trial
Background
The frequent co-occurrence of depression and substance use disorders (SUDs) is well documented both in Australia and internationally [1–9], with epidemiological studies suggesting that affective disorders are up to 4.7 times more prevalent among substance dependent samples compared to the general population [10–12]. Particular cause for concern is the high prevalence of current major depression among treatment seeking substance users, with studies reporting rates as high as 20–55 % [2, 4, 13–15]. Despite evidence that depression is linked to poorer treatment outcomes [16–20], the development and assessment of behavioural interventions for depression among substance users has received little empirical attention.

Impact of depression on treatment for drug dependence
Among substance users, depression has been associated with a more severe and protracted illness course, poorer social and occupational functioning, greater use of health services, an increased risk of post-traumatic stress disorder, higher risk of suicidal behaviours, and an increased risk of relapse in substance use problems [20–22]. The Australian Treatment Outcome Study (ATOS), a longitudinal study of treatment outcomes for heroin dependence, demonstrated that across a 3 year follow-up period clients who met DSM-IV criteria for major depression in the month preceding interview were more likely to be using heroin and other drugs, to be heroin-dependent, sharing needles, experiencing injection-related health problems, engaging in crime and were in poorer physical and mental health than non-depressed clients [20]. Depression was the only consistent predictor of poorer treatment outcome across the 3 year period [20]. Clearly, co-occuring depression and SUDs presents a complex clinical challenge for treatment providers that requires further empirical attention.

Depression and SUDs, when considered as separately occurring disorders, can be attributed to a number of environmental, genetic and neurobiological factors. In contrast, the mechanisms underlying these conditions as they co-occur are not well understood [23]. Four main hypotheses have been proposed to explain this comorbidity [24]. The self-medication hypothesis suggests that substance dependence occurs as a result of repeated substance use aimed at relieving the symptoms of depression. Secondly, depressive symptoms may develop as a direct result of taking substances or as part of withdrawal symptoms when substance use stops (e.g. substance-induced depression). Thirdly, depressive symptoms may develop in response to the lifestyle associated with using substances. Alternatively, both disorders may share common psychological or biological antecedents, thereby increasing the likelihood that they will co-occur. Regardless of which disorder came first, once co-occurring SUD and depression has been established, each may act to maintain or exacerbate the other [24].

Current treatment protocols for co-occurring depression and SUDs
While treatment has traditionally been determined based on the temporal relationship between depression and SUDs (i.e., treating the disorder with the earlier onset first), there are practical difficulties in reliably diagnosing primary and secondary conditions [25]. It has been suggested that the primary/secondary distinction is immaterial once depression and SUDs have surfaced [26], and that the focus of treatment should be on the impairment and distress caused by symptoms, as opposed to diagnostic sub-type classification, or the model of aetiology [27].

There is some evidence, albeit limited, for the effectiveness of cognitive behavioural therapy (CBT) either alone or in combination with antidepressant use for the treatment of co-occurring depression and SUDs [28]. Unfortunately, however, only a handful of methodologically sound studies have been conducted to date, and these have focused on alcohol use outcomes, with limited reports on other substance use outcomes. While there is support for the use of CBT in the treatment of depression and co-occurring tobacco [29] and alcohol dependence [30], there are a number of difficulties when implementing depression focussed CBT treatment in a population dependent on a variety of licit and illicit substances, as outlined by Daughters and colleagues [31]. CBT focuses on complex cognitive techniques, which may be too cognitively challenging for chronic substance users with cognitive deficits and low education levels [32, 33]. Its time-consuming nature makes it difficult to incorporate into existing substance abuse treatments [34] and it requires a high level of training in complex therapy based treatments, which staff may not be able to deliver in traditional drug and alcohol treatment settings [35].

Behavioural activation
A treatment that may be better suited for use among substance users is behavioural activation. According to this approach, symptoms and behaviours characteristic of depression arise when susceptible people experience problems that significantly reduce their ability to gain positive reward from their environment [36]. Behavioural activation is a structured treatment for depression designed to activate clients in ways that are tailored to increase rewarding experiences in their lives [36]. It is an action oriented approach that requires between session practice by clients, with therapists and clients working collaboratively to develop activation tasks for clients to complete outside the session and trouble-shoot obstacles that may arise. Empirical evidence suggests that behavioural
activation therapy is just as effective as CBT [37, 38], and is more time efficient and less complex when compared to most other treatments for depression [39]. Behavioural activation therapy has been shown to be an efficacious, cost-effective alternative to cognitive therapy and antidepressant medication [40, 41].

Behavioural Activation Treatment for Depression (BATD) [39] is a brief manualised treatment which employs activity scheduling and other behavioural techniques within a framework applying matching law [42] to understand depression. This law suggests that depression persists when (a) reinforcement available for non-depressed (healthy) behaviour is low or non-existent, or (b) depressed (unhealthy) behaviour provides a relatively high degree of reinforcement [39]. Depression is therefore seen as the result of both decreased reinforcement for non-depressed, healthy behaviours, and increased reinforcement for depressed behaviours [43]. The structured BATD protocol seeks to increase non-depressed behaviour by providing exposure to the positive consequences of healthy behaviour, and has shown promise in treating depression among substance users [31, 44]. The manual was recently revised ([BATD-R; [45]), to improve delivery and patient acceptability.

Evidence base for BATD
Lead developers of the manual, Lejeuz and Hopko, first pilot tested BATD among psychiatric inpatients suffering depression, and yielded a large pre-to-post treatment effect size (d = .73) for depression symptoms [46]. BATD gained additional support from three small randomised controlled pilot trials [31, 44, 47]. Daughters and colleagues (2008) added a behavioural intervention for depression (BATD) to inpatient treatment for illicit drug use (Lets Act!; N = 44) [31]. Those who received the Lets Act! intervention had significantly greater improvements in depression at post-treatment and 2-week follow-up compared with standard care alone. A subsequent trial compared Lets Act! with a time matched control treatment (supportive counselling), and found that while both groups showed a significant reduction in depressive symptoms on completion of treatment, retention in drug treatment was significantly greater in the behavioural activation group [44]. No follow-up data was collected beyond treatment completion. Another randomised controlled trial (N = 68) involving adult smokers with mildly elevated depressive symptoms and seeking smoking cessation treatment, found that participants allocated to 'Behavioural Activation Treatment for Smoking (BATS)', which was adapted from BATD, reported greater smoking abstinence, and a larger reduction in depressive symptoms at 16- and 24-week follow-up, than those who received standard smoking cessation treatment [47].

While the results of these trials are promising, and suggest preliminary support for the feasibility, acceptability and efficacy of brief behavioural activation treatment for improving mood and substance use outcomes, further research is needed. BATD-R was initially developed for use in the United States (US) and its efficacy has not been assessed in drug treatment services outside the US, among substance users in outpatient drug and alcohol treatment settings, or over long-term follow-up (i.e., 12-months) in either residential or outpatient drug treatment settings. The three clinical trials conducted to date have also all used a group rather than individual format.

Methods/design
Trial aims & hypotheses
The primary aim of the proposed trial is to determine the efficacy of a modified version of BATD-R (Activate) in reducing depressive symptoms among individuals with SUDs who are currently undergoing Residential Rehabilitation (RR) or Opioid Substitution Therapy (OST). It is hypothesised that:

1. Participants who receive Activate will demonstrate greater reductions in symptom severity for (i) depression and (ii) substance dependence, 3- and 12-months post baseline, compared to those who only receive treatment as usual.
2. Activate will be a feasible approach to treating comorbid depression and substance dependence, as measured by treatment retention and client satisfaction.

The secondary aim of the trial is to investigate the impact of other factors that may moderate or mediate the Activate treatment response. Secondary outcome measures will include those related directly to the therapy (environmental reward, behavioural activation), and those concerned with mental health (anxiety symptoms, social phobia, borderline personality disorder, traumatic events, rumination, distress tolerance, suicide history and sleep).

Trial design
The Activate study is a parallel, single blind, superiority randomised controlled trial. Participants will be randomly assigned to receive either Activate (n = 100) or treatment as usual (TAU; n = 100), stratified by treatment modality (RR and OST). Treatment as usual is the comparator group, as it is clinically important to determine whether Activate adds any benefit in terms of improved depression symptomatology and reduced dependence symptoms, beyond that gained from usual care (i.e. RR or OST). Separate randomisation schedules will be used for the two
treatment modalities. To reduce the risk of bias, minimisation, a dynamic random allocation technique, will be completed by someone independent of the research team using Minim-Py [48]. Gender and depression severity have been identified as significant prognostic factors and minimisation will ensure classification of participants with respect to these variables. Depression severity will be categorised according to BDI-II score, as mild (14–19), moderate (20–28) or severe (29–63) [49]. Minimisation has been shown to have both theoretical and practical validity, in particular it is considered an effective randomisation tool in clinical trials of small to moderate sample size (approximately, $N = 200–400$) with multiple prognostic factors to be considered [50–52].

The National Health and Medical Research Council of Australia (NHMRC) provided a project grant (#10444625) enabling the Activate study to be conducted. The funding period was initially February 2013 to December 2015, but was extended to December 2016 to accommodate extension of the baseline recruitment phase. Ethics approval was obtained from the University of New South Wales Human Research Ethics Committee (HREC) (Ref No: HC13155), and the Northern Sydney Local Health District HREC (Ref No: HREC/12/HAWKE /404). A model of the information and consent form used is available as supplementary material (Additional file 1). The study has been prospectively registered in the Australian and New Zealand Clinical Trials Registry (ACTRN12613000876796, 7/08/13). Any changes to the trial protocol which may impact the conduct of the study, the benefit to the patient or patient safety, will require a formal amendment to the protocol. Approval for such amendments will be sought from the HREC and the trial registry will be updated. See Table 1 for the WHO Trial Registration Data Set. Additional information regarding groups overseeing the trial, insurance coverage, and authorship guidelines can be found in the supplementary material (Additional file 1).

Sample size calculation

Power analysis on the primary outcome variables (i.e., severity of dependence and depressive symptoms) was conducted using Power Analysis and Sample Size software [53]. Based on previous research, including the longitudinal study of treatment outcomes for heroin dependence (ATOS; [20]), an exchangeable working correlation matrix and a within-subject correlation of $\rho^I = .60$ for dependence and $\rho^I = .023$ for depression was assumed. The proposed final sample size of 160 will allow for the detection of clinically meaningful differences between the treatment and control groups. Specifically, it will allow for the detection of a time-averaged difference of $3$ in severity of substance dependence with a standard deviation of $5$ ($\beta = 99 \%$ power; $\alpha = 0.05$); a $15 \%$ difference in the prevalence of substance dependence ($\beta = 96 \%$ power; $\alpha = 0.05$); a difference of $5$ in BDI-II scores with a standard deviation of $15$ ($\beta = 81 \%$ power; $\alpha = 0.05$); and a $15 \%$ difference in the prevalence of major depression ($\beta = 93 \%$ power; $\alpha = 0.05$). To allow for an expected attrition rate of $20 \%$, the initial sample will be $200$, with the aim of recruiting $50 \%$ of participants from RR and $50 \%$ from OST.

Participants will be $18$ years of age or older, literate in English, willing to give locator information, and must have been in RR for at least $1$ week or OST for at least $3$ months. RR clients must have used a substance (i.e., alcohol, methamphetamines, cannabis, cocaine, hallucinogens, illicit benzodiazepines, heroin or other opioids) at least four times in the month prior to detoxing, and OST clients must have used a substance at least four times in the past month. If alcohol is the only substance used, individuals need to have consumed four or more standard drinks on at least $4$ days in the month before detoxing/past month. The depression screening criteria from the Composite International Diagnostic Interview 3.0 (CIDI; [54, 55]) must be endorsed, indicating that the individual has experienced symptoms of depression that persisted for $2$ weeks or longer in the month before detoxing/past month, and these symptoms must be ongoing. Depression symptom severity will be assessed using the Patient Health Questionnaire (PHQ-9; [56]), with a score in the mild to severe range (i.e., 5–27) required to be eligible for the study.

Active suicidality, psychosis and organic or traumatic brain injury will exclude an individual from entering the study. Suicidality is assessed by the PHQ-9 during the screening interview. Participants are asked “in the past $2$ weeks/2-weeks before detox, have you been bothered by thoughts that you would be better off dead.” If participants indicate that they have been bothered by these thoughts, the research officer then probes further, using questions taken from the Suicide Assessment Kit screener [57], to determine whether these thoughts are ongoing, how long they have been having the thoughts, how intense they are, how likely it is that they will act on these thoughts in the near future, whether they have ever attempted suicide previously, and if so, how recently. Individuals who have attempted suicide in the past $6$ months and for whom nothing has changed (i.e., they have received no intervention, or nothing has changed in their circumstances to reduce their risk), will be excluded from the study, and given a referral for appropriate support. If the thoughts are intense or the participant deems it likely that they will act on them in the near future, they are asked about any current plans and prior attempts, and are referred to an appropriate staff member at the treatment service for ongoing support and management.

Suicidality is assessed further as part of the baseline interview. The BDI-II and CIDI 3.0 both ask questions about suicidal thoughts, with the CIDI also asking about
Table 1  Trial registration data set as recommended by the World Health Organization (WHO)

| Data category                                      | Information                                                                 |
|---------------------------------------------------|------------------------------------------------------------------------------|
| Primary registry and trial identifying number     | Australian and New Zealand Clinical Trials registry, ACTRN12613000876796    |
| Date of registration in primary registry          | 7 August, 2013                                                              |
| Secondary identifying numbers                     | Universal Trial Number U1111-1142-2213                                      |
| Source(s) of monetary or material support         | National Health and Medical Research Council                                 |
| Primary sponsor                                    | National Drug & Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052 |
| Contact for public queries                        | Joanne Ross (j.ross@unsw.edu.au)                                            |
| Contact for scientific queries                    | Joanne Ross National Drug & Alcohol Research Centre, UNSW, Sydney, Australia |
| Public title                                       | Treatment for depression among people with substance use disorder: The Activate Study |
| Scientific title                                  | The efficacy of behavioural activation therapy for co-occurring depression and substance use disorder: The Activate Study |
| Countries of recruitment                          | Australia                                                                   |
| Health condition(s) or problem(s) studied         | Depression and Substance Use Disorder                                       |
| Intervention(s)                                   | The intervention is Behavioral Activation Treatment for Depression (BATD-R), modified for use in outpatient and in-patient drug and alcohol treatment settings (Activate). Comparator: Treatment as usual i.e. Residential Rehabilitation (RR) or Opioid Substitution Treatment (OST). |
| Key inclusion and exclusion criteria               | Inclusion criteria:  
a) 18 years of age or older  
b) Literate in English  
c) Willing to give locator information  
d) Entered RR within the last month or in OST for at least 3 months  
e) Endorse CIDI 3.0 depression screening criteria  
f) Score at least in the mild range on PHQ-9  
g) Substance use in the month prior to interview  
Exclusion criteria:  
a) Active suicidality  
b) Active psychosis  
c) Organic or traumatic brain injury  
d) Not living in the greater Sydney metropolitan area  
e) Not living in the community in the month prior to baseline |
| Study type                                         | Interventions. Allocation: randomised; intervention model: parallel assignment; Masking: the research officers assessing outcomes are blind to the allocation  
Primary purpose: Treatment |
| Date of first enrolment                            | 12/08/2013                                                                  |
| Target sample size                                | 200                                                                          |
| Recruitment status                                 | Recruitment completed. Analysis ongoing.                                    |
| Primary outcome(s)                                 | 1) Depression Severity  
- Beck Depression Inventory (BDI-II) score  
- Composite International Diagnostic Interview 3.0 (CIDI) assessment of Major Depression.  
2) Substance Use Disorder  
- CIDI assessment of substance use disorder  
- Severity of dependence scale (SDS) |
| Key secondary outcomes                            | 1) Treatment feasibility as assessed by treatment retention and client satisfaction  
(assessed using the Client Satisfaction Questionnaire on completion of the Activate intervention)  
2) Factors that influence the efficacy of the modified BATD-R (Activate) including client and treatment characteristics (assessed at baseline, 3 and 12 months). |

Date and version identifier: Issue date: 17 Feb 2016  
Protocol amendment number: 01 Authors: KP, JR  
Revision chronology:  
00, 7 August, 2013 Original  
01, 17 February, 2016 Amendment 01:  
Two exclusion criteria, i.e. d) not living in the greater Sydney metropolitan area and e) not living in the community in the month prior to baseline, were added, as omitted from the original list  
Actual date that the first participant entered the study was added (12.08.13)  
Date of last participant enrolment was changed from 3.12.14 to 26.02.15. The baseline recruitment phase was extended due to delays with ethics and to help boost recruitment  
List of recruitment sites was updated  
File updated to indicate that Ethics Approval was obtained from Northern Sydney Local Health District HREC on 4 December 2013
plans and attempts [49, 55]. Additional questions about the lifetime number of suicide attempts and recency of the last attempt are also asked. In situations where suicidality is indicated, the research officer uses the additional probing questions described above to assess their current risk, and to determine whether there is a need for exclusion from the study and referral for additional support. It is possible for a person with a current plan and thoughts of suicide to be recruited to the study provided the risk is not deemed imminent, and the treatment service is made aware of the suicidal thoughts and plan.

As part of the screening questionnaire, potential participants are asked whether they have ever been diagnosed with bipolar, mania, or schizophrenia. If the response is yes, (or if the individual reports being prescribed antipsychotics during the baseline interview), the project psychologist will meet briefly with them and ask them whether they ever see or hear things that other people cannot see or hear, whether the hallucinations are believed to be drug induced, whether the hallucinations are current, and how these are managed. These individuals are also asked about having unusual thoughts or beliefs. The psychologist then makes a clinical decision about their eligibility for the study. Self-report of having received a diagnosis of traumatic brain injury, as ascertained during the screening interview, is also a reason for exclusion.

Exclusion from the study in all of the above cases is based on the individual’s inability to effectively engage with, and thus benefit from, the type of intervention offered. Decisions to exclude on the basis of suicidality, psychosis or traumatic brain injury will all be made in consultation with the project coordinator and/or a project psychologist prior to randomisation. Alternate referral for treatment will be provided where necessary. Additionally, for reasons of feasibility in providing the Activate intervention and contacting participants for follow-up, clients will be excluded if they do not live in the Greater Sydney Metropolitan, Central Coast or Hunter New England regions. To ensure that participants have been at liberty to use substances in the month prior to detox or past month, individuals not living in the community (e.g., incarcerated) during that period will be excluded.

**Study procedure**

**Sample site recruitment**

Participants will be recruited from RR services and OST clinics in greater Sydney metropolitan area, the Central Coast, and Hunter New England Health regions. Management staff will be contacted by the project coordinator to determine their initial interest in being involved. A letter outlining the purpose of the trial, and what will be required of the agency should they choose to participate, will be sent to the services. On confirmation of intent to participate, the research team will meet with the staff to discuss logistics, and recruitment of study participants will commence.

**Screening**

Staff in the RR and OST services will inform clients that the University of New South Wales is conducting a study examining mood and substance use. They will direct those interested in hearing about the study and being screened for eligibility, to one of the project’s research officers who will be on-site to conduct the screening to help maximise recruitment. Informed written consent will then be sought by the research officers from eligible clients interested in participating, locator information to facilitate follow-up will be collected, and the baseline interview conducted. The research officers (honours graduates in psychology) have been trained in the assessment interview by the investigators (MT, JR and KM). Participants will be informed that they are free to withdraw from the study at any stage. Recruitment will occur in ten treatment services over a period of 18 months. The locations of the treatment services are listed in the Australian and New Zealand Clinical Trials registry.

**Assessment occasions**

The structured baseline interview will be administered by the research officers, followed by randomisation of participants to one of two groups; (1) TAU, or (2) Activate plus TAU (Fig. 1). The allocation sequence will be computer-generated by someone independent of the Activate team. The project coordinator will then inform the psychologist about the allocation, and they will notify the study participant. Follow-up interviews for the Activate and TAU groups will parallel each other, conducted at 3-months and 12-months post-baseline. Primary and secondary outcome measures will be assessed at all three assessment occasions, with the exception of client satisfaction, which will be assessed on completion or cessation of the Activate intervention. Follow-up interviews will be administered by the project’s research officers who will be blind to group allocation. The baseline and follow-up interviews are estimated to take 60–90 min to complete. Participants will be reimbursed AU$30 per interview for out of pocket expenses.

**Locator information**

A locator form will be used to record participant information that may be used to facilitate follow-up. This information will be collected at baseline and updated on both follow-up occasions. Consent to the study also provides permission for researchers to locate the participant by various means, such as social media, telephone directories, court lists, electoral rolls, and treatment services. These methods are based on those used in ATOS
which achieved follow-up rates of 89, 80, 76, and 70% at 3-, 12-, 24-, and 36-month follow-ups respectively [58].

Data management
To maintain confidentiality of participant data, all participant information will be stored in locked filing cabinets at the National Drug and Alcohol Research Centre, with access restricted to the research team. All records that contain names or other personal identifiers (such as locator forms and consent forms), will be stored separately from questionnaires, which will be identified by a participant identification number. All local databases will be secured with password protected access systems. Data entry will be conducted by the research officers. To maximise accuracy and consistency of data entry, a data dictionary will be used to define the variables and specify how they are to be coded. To promote data quality value range checks and consistency checks will be performed.

Measures
Baseline and follow-up interviews
The baseline and follow-up interviews will examine demographics, drug use history, treatment history (for substance use and depression), and will use validated instruments to assess a) the primary treatment outcomes of depression and substance dependence, and b) secondary treatment outcomes related to the therapy and mental health. Demographic measures will include age, gender, level of education, employment status, main source of income, marital status, living arrangements, and prison history. A drug use history (including age of first use, and the number of days used in the last 30 and 90 days), will be obtained for heroin, other opiates, methamphetamine, cocaine, hallucinogens, antidepressants, benzodiazepines, alcohol, cannabis, inhalants and tobacco. Prescription drug use will also be recorded. Drug treatment and depression treatment history will assess current treatment(s), the age at which they first sought treatment, number of times they have commenced treatment, and the recency of these treatments. Information will also be obtained on the participants’ history of suicide, self-harm, and occasions where they lost consciousness as the result of a head injury.

Primary outcome measures
Depression: The severity of depression symptoms in the past 2 weeks will be assessed using the 21-item Beck

---

![Flow Diagram of Trial Progression](https://i.imgur.com/5Q5Q5Q5.png)

**Fig. 1 Flow Diagram of Trial Progression**
Depression Inventory (BDI-II; [49]). Each item comprises a list of four statements arranged in increasing severity about a particular symptom of depression. Scores range from 0 to 63, with higher total scores indicating more severe depressive symptoms. Depression can then be interpreted as minimal (0–13), mild (14–19), moderate (20–28), or severe (≥29). The BDI-II has been widely used in both clinical and non-clinical studies, has shown good test-retest reliability (Pearson’s \( r = .73-.96 \)), and high internal consistency (Chronbach’s \( \alpha = .83-.96 \)) [59]. A past month diagnosis of major depression will be ascertained by completing the CIDI 3.0 depression section, modified to assess the presence of symptoms in the past month [54, 55]. The CIDI 3.0 major depression module has been found to have moderate concordance with the Structured Clinical Interview for DSM (SCID) (area under the receiver operator curve; AUC = 0.75) [60].

Substance Dependence: Psychological components of dependence will be measured using the Severity of Dependence Scale (SDS; [61]). Each of the 5 items is scored on a 4-point scale, ranging from 0 to 3. A total score is obtained, with higher scores indicating a higher level of dependence. The inter-item reliability has been demonstrated across five drug using samples, with Cronbach’s alpha values ranging between 0.8 and 0.9 [61]. A diagnosis of substance dependence will be established using the CIDI 3.0, with the number of dependence criteria endorsed (0–7) being used as an indicator of severity [54]. The CIDI 3.0 substance use disorder module has been found to have moderate concordance with the SCID (Alcohol dependence, AUC = 0.72; Drug dependence, AUC = 0.62) [60].

Problematic alcohol use will be screened for using the 4-item CAGE questionnaire [62]. Scores range from 0 to 4, with scores greater than or equal to 2 considered to be clinically significant. The CAGE has demonstrated high test-retest reliability (\( r = 0.80–0.95 \)), and adequate correlations (\( r = 0.48–0.70 \)) with other screening instruments such as the Alcohol Use Disorders Identification Test (AUDIT) and Short Michigan Alcohol Screening Test (SMAST) [63].

**Symptom monitoring and secondary outcome measures**

The Patient Health Questionnaire-9 (PHQ-9) will be used in the initial screening interview, and then by therapists to monitor depressive symptoms among the intervention group [56]. The PHQ-9 is a nine-item screener for major depression and a measure of depression severity, which assesses the presence of each of the nine DSM-IV criteria for major depression in the preceding 2 weeks. Scores range from 0 to 27, as each of the nine items can be scored from ‘0’ (not at all) to ‘3’ (nearly every day) [56]. Major depression is indicated if 5 or more of the 9 depressive symptom criteria have been present at least “more than half the days” in the past 2 weeks, and 1 of the symptoms is depressed mood or anhedonia. The PHQ-9 has demonstrated excellent internal reliability (Chronbach’s \( \alpha = 0.86–0.89 \)), and test-retest reliability (\( r = 0.84 \)) [56]. Criterion validity has been demonstrated in a sample of 580 primary care patients who were independently re-interviewed by a mental health professional. Receiver Operator Curve (ROC) analysis showed that the area under the curve for the PHQ-9 in diagnosing major depression was 0.95, suggesting that it discriminates well between persons with and without major depression [56].

Client satisfaction will be assessed after completion of Activate therapy using the Client Satisfaction Questionnaire, an 8-item scale designed to measure and assess client satisfaction with health and human services (CSQ-8; [64]). The CSQ-8 elicits the client’s perspective on the value of services received. Responses are given on a 4-point Likert scale. Scores range from 8 to 32, with higher scores indicating greater satisfaction. The CSQ-8 has demonstrated excellent reliability and internal consistency (Chronbach’s alpha 0.92 to 0.93) [64]. Secondary outcome measures, including those associated with behavioural activation therapy and mental health will be assessed at baseline, 3- and 12-month follow-up (Table 2).

**Intervention**

The trial will use a modified version of the BATD-R manual (Activate), which involves 10 individual, weekly 60-min sessions, with a psychologist from the research team. The 10-session format allows for the inclusion of topics deemed important for the target population, and there is evidence that clinically significant improvements in depression symptoms can be achieved within this period [45]. The BATD-R manual was modified to include psychoeducation about the relationship between substance use and depression. To assist in establishing treatment goals in relation to their substance use, some motivational interviewing techniques were incorporated. Namely, this involved asking questions to elicit change talk, such as, ‘What would you like to be different about your current situation?’ Other additions include the provision of a list of behavioural techniques for managing craving [65], and a simple breathing exercise. Given the high levels of psychiatric comorbidity among substance users in drug treatment [66, 67], self-soothing and grounding techniques have been included for managing emotional distress, and defusion exercises for the management of unhelpful thoughts. Participants may choose to withdraw from the intervention at any time, but will still be contacted for follow-up assessment, unless they have withdrawn from the study.

To encourage treatment attendance participants in Activate will receive a reminder call the day prior to each session to confirm their appointment for the following day.
and appointment times will be highly flexible throughout the treatment program, with the option to reschedule appointments if required. Therapists will keep logs of clients’ attendance at sessions.

The use of project therapists, as opposed to existing clinicians within treatment agencies, has been chosen to minimise the risk of contamination of the control group. In order to avoid the outcome of Activate being attributed to a single therapist bias, two clinical psychologists will be employed. Both psychologists will receive extensive training in treatment delivery, provided by the lead developer of BATD-R, Carl Lejuez, and will be supervised by a senior clinical psychologist with experience in the treatment of depression and substance use. The Activate treatment manual will be taken into each session by the therapist to ensure all proposed areas are covered. The therapist will also complete a session checklist, with any deviations from the therapy manual recorded in the clinical notes kept for each session. Weekly clinical supervision will be held with the chief investigators, where session checklists will be monitored. In addition, all treatment sessions will be audio-recorded to allow for assessment of treatment fidelity.

**Overview of treatment**

Session One covers the procedural aspects of treatment such as conditions of confidentiality, the recording of sessions, suicide risk assessment as well as guidelines for treatment and emphasising the importance of attending each weekly session. Session One also provides psycho-education about the role of substance use in depression, explores the participant’s current situation and their ideal life, reviews the treatment rationale as well as introducing behaviour monitoring. The first session introduces the weekly homework assignment which is repeated each subsequent session. This involves the monitoring of activities on an hourly basis with the participant also providing ratings on the enjoyment and importance of each activity on a numerical scale from 1 to 10, as well as a rating of their overall daily mood from 1 to 10 (1 being low and 10 being high).

| Table 2 Schedule of assessments |
|----------------------------------|
| Domain                          | Measure                                                                 | Screening | Baseline | 3 month follow-up | 12 month Follow-up |
| **Eligibility**                  |                                                                        |           |          |                  |                   |
| Depression symptoms             | Patient Health Questionnaire (PHQ-9) [56]                               | +         | –        | –                 | –                 |
| Depression screener             | CIDI 3.0 Depression screener questions [54, 55]                          | +         | –        | –                 | –                 |
| **Primary outcome measures**    |                                                                        |           |          |                  |                   |
| Substance dependence            | CIDI 3.0 Substance dependence (past month DSM-IV TR) [54]                | –         | +        | +                 | +                 |
|                                | Severity of Dependence Scale (SDS) [61]                                 | –         | +        | +                 | +                 |
| Depression                      | CIDI 3.0 Major depression (past month DSM-IV TR) [54, 55]                | –         | +        | +                 | +                 |
|                                | Beck Depression Inventory-II (BDI-II) [49]                               | –         | +        | +                 | +                 |
| **Secondary outcome measures**  |                                                                        |           |          |                  |                   |
| Behavioural activation          | Behavioural Activation for Depression Scale Short Form (BADS-SF; [70]) | –         | +        | +                 | +                 |
| Anxiety                         | Beck Anxiety Inventory (BAI; [71])                                      | –         | +        | +                 | +                 |
| Social phobia                   | CIDI 3.0 Social Phobia (past month DSM-IV-TR) [54]                       | –         | +        | +                 | +                 |
|                                | Liebowitz Social Anxiety Scale [72, 73]                                  | –         | +        | +                 | +                 |
| Traumatic events & trauma       | PTSD trauma checklist from the CIDI 3.0 [54] and the                     | -         | +        | +                 | +                 |
| symptoms                        | Post-Traumatic Stress Disorder Checklist – Civilian Version (PCL-C; [74]) |           |          |                  |                   |
| Borderline Personality Disorder | International Personality Disorders Examination (IPDE; [75])            | –         | +        | +                 | +                 |
| Environmental Reward            | Environmental Rewards Observation Scale (EROS; [76])                   | –         | +        | +                 | +                 |
| Rumination                      | Perseverative Thinking Questionnaire (PTQ; [77, 78]) and Ruminative     | –         | +        | +                 | +                 |
|                                | Response Scale (RRS; [79])                                              |           |          |                  |                   |
| Distress Tolerance              | Distress Tolerance Scale (DTS; [80])                                    | –         | +        | +                 | +                 |
| Sleep disturbance               | Pittsburgh Sleep Quality Index (PSQI; [81])                             | –         | +        | +                 | +                 |
| Chronic physical conditions     | As outlined by the Australian National Health Priority Area [82, 83]     | –         | +        | +                 | +                 |
Session Two begins with the revision of substance use, depression symptoms and suicide risk, followed by a detailed review of the daily monitoring forms completed that week. This review occurs in all subsequent sessions. Enjoyment and importance ratings are considered for each activity and participants explore any difficulties that they had completing monitoring forms. The treatment rationale is reviewed prior to introducing the concept of life areas (relationships; education/career; recreation/interests; mind/body/spirituality and daily responsibilities). The majority of the session focuses on exploring the participant’s values within each of the life areas and generating activities that are associated with each area. Finally, participants are introduced to a list of behavioral activities to assist in coping with cravings for substances. These include using delay and distract techniques, managing hunger and thirst, using controlled breathing techniques, imagery exercises such as “urge surfing”, seeking social support, and using positive self-talk.

During the third session, participants continue to generate activities that are value-based for each life area. They then choose fifteen of these activities and rank them in order from easiest to hardest taking into account the level of expected enjoyment and importance of each activity. The participant is encouraged to include some activities that they are already engaged in. Session Three concludes with the introduction of the two brief behavioral techniques for managing emotional distress, these include a self-soothing exercise (where the client is asked to use their five senses to create more soothing moments in their day), and a breathing exercise where participants slow their breathing and think of the word “relax” when exhaling.

In Session Four participants revisit the activity list from the previous session and choose activities to schedule into their monitoring forms for the upcoming week. They progress from easier to harder activities and have the opportunity to reassess the order of activities throughout sessions. The process of selecting activities from their list occurs each session until the end of treatment. Participants are encouraged to choose between one and three new activities each week from a variety of different life areas. Session four ends with the introduction of a defusion exercise (e.g., using repetition or singing the thought).

Session Five introduces the concept of contracts with significant others. Participants are encouraged to select an activity that they have found difficult to complete and then select three friends or family members who may be able to assist them to complete this activity. The aim is to increase social support and increase enjoyment in completing activities. Sessions Six to Ten reinforce material previously introduced with a focus on activity selection and monitoring. In Session Six a simple grounding exercise is introduced at the end of the session (notice five things you can see, hear and feel). Similarly, at the end of Session Eight a basic mindfulness exercise is introduced for participants to practice.

Session Ten concludes treatment with a list of skills achieved and an opportunity to explore the management of potential setbacks. Throughout treatment, participants are encouraged to recognize patterns of depressed behavior and the way in which engaging in enjoyable and important activities may impact their overall mood.

Prior to each session participants will complete the PHQ-9 [56] and be asked how many days they have used substances (alcohol, cannabis, benzodiazepines, heroin, other opiates, methamphetamine, and ‘other’) in the past week. This will enable therapists to monitor depressive symptoms and substance use throughout treatment, and help to identify unfavorable changes in symptoms. If concerned for the safety and wellbeing of the participant, the therapist will consult with the project coordinator, additional support services will be offered to the participant, and it will be determined whether or not ongoing therapy is appropriate for them. Although unlikely, any adverse events attributed to the intervention will be reported to the HRECs. The participant information sheet also instructs participants to contact the project coordinator if they experience “significant distress as part of this study” and provides contact details for the ethics secretariat should they wish to make a complaint about the conduct of the study.

**Treatment as usual**

The control group will receive the model of care provided in accordance with standard practice at participating RR and OST services, and will be delivered by agency staff. In addition to standard drug and alcohol treatment, clients in RR may receive additional treatment from case workers or in-house psychologists. Similarly, in addition to methadone or buprenorphine maintenance for managing heroin dependence, OST clients may also receive counselling for depressive symptoms, antidepressant medication where appropriate, and referral to mental health services when required. All treatment for depression received as a part of TAU will be recorded in participant interviews. These will be controlled for in comparative analysis of treatment outcomes.

**Statistical analysis**

The proportion of screened clients entering the study will be determined. T-tests and chi-square analyses will be conducted to determine if those who did not enroll in the study were systematically different from those who did. T-tests and chi-square analyses will also be conducted to determine if there were any significant differences between the treatment and control groups at baseline. For outcome analyses, both intention-to-treat (i.e. analyses
include all randomised participants, regardless of protocol adherence) and per-protocol analyses (i.e. where the intervention group only includes participants who received at least one session) will be conducted. Categorical and continuous measures of outcome will be examined using mixed or marginal longitudinal models.

To evaluate treatment fidelity, 10% of each therapist’s sessions will be rated for compliance with the treatment manual. Interim descriptive analyses will take place at each assessment stage (including the baseline assessment), to assist with the monitoring of data collection and data entry. These analyses will be conducted by the research officers, who will not have access to the treatment allocation variable. Final stage analyses will be carried out after completion of the 12 month follow-up.

**Dissemination of results**

The research team intend presenting the findings of this trial at professional seminars, national and international conferences, and in manuscripts submitted for publication in peer-reviewed journals. Results will also be reported to the UNSW and Northern Sydney Local Health District HRECs. Only aggregated group data will be reported and no individuals will be identified.

**Discussion**

This protocol presents the design of the Activate study, a randomised controlled trial, which seeks to evaluate the efficacy of a modified version of BATD-R (Activate) among individuals in treatment for SUDs. The primary aim of the study is to investigate the efficacy of the Activate intervention in comparison to treatment as usual, in reducing symptoms of depression and substance dependence. For the Activate intervention group, treatment retention, client compliance, and client satisfaction will be assessed. The secondary aim of the study is to examine whether other factors, including those associated with therapy (environmental reward, behavioural activation), and those concerned with mental health (anxiety and social phobia, borderline personality disorder, traumatic events, rumination, distress tolerance, and sleep), impact upon the Activate treatment response.

**Strengths and limitations**

A strength of the Activate study is that it is the first randomised controlled trial to evaluate the efficacy of behavioural activation therapy for depression among individuals in both inpatient and outpatient substance abuse treatment settings, and in an individual format. Follow-up assessments will occur at 3- and 12-months post-baseline in both the Activate intervention group and the control (TAU) group, which will provide an opportunity to evaluate the long-term effects of Activate among this population for the first time. Primary outcomes of severity of depression and dependence will be assessed by research officers who will be blind to treatment allocation, using validated measures. The incorporation of some motivational interviewing techniques, a brief relaxation strategy, and psychoeducation about the role of substance use in depression targets the intervention more specifically for substance users. Defusion exercises, self-soothing and grounding techniques have been included to equip participants with skills for managing rumination and emotional distress, which are prevalent among this group [68], so they can attend to the BATD-R protocol more fully.

One limitation of the Activate study is excluding individuals who have active suicidality, self-harm or psychosis, and those who report organic or traumatic brain injury. This may be considered to reduce the generalisability of results to a real world sample. However, these exclusion criteria were based on the individual’s likely inability to effectively engage with, and thus benefit from the type of intervention offered. A potential challenge for the study will be retaining participants, as individuals with SUDs are traditionally very difficult to follow-up. To maximise follow-up rates, research officers will build good rapport with participants, obtain detailed contact information to help with locating participants, reinforce to participants the importance of conducting follow-ups, and financially compensate participants for the time required to complete the interviews (AUS$30). These methods have been utilised in previous studies among substance users, which achieved commendable 12-month follow-up rates of around 80% [20, 69].

**Conclusion**

Integrated treatment is recommended in people with psychiatric illness comorbid with substance use problems. Yet, there are currently few evidence based treatment options for co-occurring depression and SUD. BATD-R is a manualised treatment that has shown promise among drug and alcohol residential rehabilitation clients [31, 44] and among psychiatric inpatients [46], but larger, longer term trials are needed to broaden the BATD-R evidence base. The Activate study will be one of the few randomised controlled trials of psychosocial treatments for this comorbidity to be conducted internationally. The findings are likely to contribute significantly to understanding the types of programs that are effective in treating this comorbidity.

**Additional files**

Additional file 1 "Activate participant information and consent form"—This file provides a model of the information and consent form used in the trial (DOC 293 kb)
Abbreviations

ATOS, Australian Treatment Outcome Study; AUC, Area under the receiver operator curve; AUD, Australian dollars; AUDIT, Alcohol Use Disorders Identification Test; BADS-SF, Behavioural Activation for Depression Scale Short Form; BAI, Beck Anxiety Inventory; BATD, Behavioral Activation for Depression; BATD-R, Behavioral Activation for Depression: Revised Treatment Manual; BDI-II, Beck Depression Inventory-II; CIDI 3.0, Composite International Diagnostic Interview version 3.0; CSQ-8, Client Satisfaction Questionnaire; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition; DTS, Distress Tolerance Scale; EROS, Environmental Rewards Observation Scale; HREC, Human Research Ethics Committee; IPDE, International Personality Disorders Examination; NHMRC, National Health and Medical Research Council of Australia; OST, Opioid Substitution Therapy; PCL-C, Posttraumatic Stress Disorder Checklist – Civilian Version; PHQ-9, Nine Item Patient Health Questionnaire; PTG, Perseverative Thinking Questionnaire; PTSD, Post-Traumatic Stress Disorder; RR, Residential Rehabilitation; SCID, Structured Clinical Interview for DSM disorders; SDS, Severity of Dependence Scale; SF-12, Short Form-12 Health Survey; SMAST, Short Michigan Alcohol Screening Test; WHO, World Health Organization.

Availability of data and materials

Data: Not applicable. Access to the trial dataset is restricted to the Activate research team, as consent has not been obtained from participants for the release of individual level data. Materials: Can be obtained from the corresponding author.

Acknowledgements

This research is funded by a National Health and Medical Research Council (NHMRC) project grant, NHMRC fellowships awarded to MT and KM, and NHMRC Centre funding. NHMRC had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. The trial sponsor is the National Drug and Alcohol Research Centre, University of New South Wales (Contact person: MT).

Authors’ contributions

MT, JR, CL, KM, SK, KB & GD are the Chief Investigators on The Activate trial. MT, JR and KM are responsible for the conduct of the study, including the grant submission, ethics clearance and training of research staff. JR, MT, KM and SK provide guidance to the research team regarding the conduct of the trial, through attendance at weekly team meetings. CL provided training in BATD-R to the clinical team, and ongoing clinical support regarding treatment delivery. GD and KB are available for clinical guidance as required. JR, KP, XL, JC, PE, & SLM were involved in the recruitment of treatment agencies. JR, KP, XL, IK and SM are responsible for participant recruitment, data collection, data entry and data verification. JC, PE and SLM are responsible for the collection of data from clinical sessions. JR, KP, XL and JC drafted the current paper. All authors read and approved the final manuscript.

Competing interests

Nil to report.

Consent to publish

Not applicable.

Ethics approval and consent to participate

Ethics approval for the study has been granted by the University of New South Wales Human Research Ethics Committee (HREC) (Ref No: HC13155), and the Northern Sydney Local Health District HREC (Ref No: HREC/12/HAWKE/404). Informed consent was obtained from all participants prior to participation in the study.

References

1. Burns L, Teesson M. Alcohol use disorders comorbid with anxiety, depression and drug use disorders. Findings from the Australian national survey of mental health and well-being. Drug Alcohol Depend. 2002;68:299–307.
2. Teesson M, Havard A, Fairbairn S, Ross J, Lynskey M, Darke S. Depression among entrants to treatment for heroin dependence in the Australian treatment outcome study (ATOS): prevalence, correlates and treatment seeking. Drug Alcohol Depend. 2005;78:309–15.
3. Mccdade K, Lucas B, Carter JD, Creft RJ, Stough C. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology (Berl). 2004;173:434–9.
4. Mcketin R, Lubman DI, Lee NM, Ross JE, Slade TN. Major depression among methamphetamine users entering drug treatment programs. Med J Aust. 2011;195:551–5.
5. Teesson M, Slade T, Mills K. Comorbidity in Australia: findings of the 2007 National Survey of Mental Health and Wellbeing. Aust N Z J Psychiatry. 2007;43:606–14.
6. Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry. 2003;64:247–57.
7. Grant BF. Comorbidity between DSM-IV drug use disorders and major depression: results of a national survey of adults. J Subst Abuse. 1997;298:91–97.
8. Rush B, Urbanoski K, Bassani D, Castel S, Wild TC, Strike C, Kimberley D, Somers J. Prevalence of co-occurring substance use and other mental disorders in the Canadian population. Can J Psychiatry. 2008;53:800–9.
9. Farrell M, Howe S, Bebbington P, Brugha T, Jenkins R, Lewis G, et al. Nicotine, alcohol and drug dependence and psychiatric comorbidity: results of a national household survey. Br J Psychiatry. 2001;179:432–7.
10. Huang B, Dawson DA, Stinson FS, Hasin DS, Ruan WJ, Saha TD, et al. Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67:1062–1073.
11. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA. 2003;289:3095–105.
12. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of Mental-Disorders with Alcohol and Other Drug Abuse—Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511–8.
13. Rounsaville BJ, Anton SF, Carroll K, Budde D, Prusoff BA, Gawin F. Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch Gen Psychiatry. 1991;48:43–51.
14. Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. Biol Psychiatry. 2004;56:793–802.
15. Burns J, Teesson M, O’Neil K. The impact of comorbid anxiety and depression on alcohol treatment outcomes. Addiction. 2005;100:787–96.
16. Greenfield S, Weiss R, Muenz L, Vagge L, Kelly J, Bello L, et al. The effect of depression on return to drinking: A prospective study. Arch Gen Psychiatry. 1998;55:259–65.
17. McKay JR, Pettinati HM, Morrison R, Feeley M, Mulvaney FD, Gallop R. Relation of depression diagnoses to 2-year outcomes in cocaine-dependent...
patients in a randomized continuing care study. Psychol Addict Behav. 2002;16:225–35.

18. Dodge R, Sindelar J, Sinha R. The role of depression symptoms in predicting drug abstinence in outpatient substance abuse treatment. J Subst Abuse Treat. 2005;28:189–96.

19. Hasan D, Liu X, Nunes E, McCloud S, Samet S, Endicott J. Effects of major depression on remission and relapse of substance dependence. Arch Gen Psychiatry. 2002;59:375–80.

20. Teesson M, Mills K, Ross J, Darke S, Williamson A, Havard A. The impact of treatment on 3 years’ outcome for heroin dependence: findings from the Australian treatment outcome study (ATOS). Addiction. 2008;103:1180–8.

21. McMillan AT, Luborsky L, Woody GE, O’Brien CP, Druley KA. Predicting response to alcohol and drug-abuse treatments—role of psychiatric severity. Arch Gen Psychiatry. 1983;40:620–5.

22. Havard A, Teesson M, Darke S, Ross J. Depression among heroin users: 12-month outcomes from the Australian treatment outcome study (ATOS). J Subst Abuse Treat. 2006;33:355–62.

23. Volkow ND. The reality of comorbidity: depression and drug abuse. Biol Psychiatry. 2004;56:714–7.

24. Nunes EV, Levin FR. Treatment of co-occurring depression and substance dependence: using meta-analysis to guide clinical recommendations. Psychiatri Ann. 2008;38:730–8.

25. Kay-Lambkin F, Baker A, Carr VJ. Drug dependence and alcohol problems. In: Baker A, Vellman R, editors. Clinical handbook of co-existing mental health and drug and alcohol problems. London: Routledge; 2007. p. 218–40.

26. Powell BJ, Perlick EC, Nickel EJ, Lisikow B, Riesenkind KD, Campion S, et al. Outcomes of co-morbid alcoholic men: a 1-year follow-up. Alcohol Clin Exp Res. 1992;16:131–8.

27. Schuckit MA, Tipp JE, Bergman M, Reich W, Hesselbrock VM, Smith TL. Psychiatric symptom severity. Arch Gen Psychiatry. 1983;40:620–5.

28. Hides L, Samet S, Lubman DI. Cognitive behaviour therapy (CBT) for the treatment of co-occurring depression and substance use: current evidence and directions for future research. Drug Alcohol Rev. 2010;29:518–7.

29. Hall SM, Muñoz RF, Reus VI. Cognitive-behavioural intervention increases abstinence rates for depressive-history smokers. J Consult Clin Psychol. 1994;62:141–6.

30. Brown RA, Evans DW, Miller IW, Burgess ES, Mueller TI. Cognitive-behavioral treatment for depression in alcoholism. J Consult Clin Psychol. 1997;65:715–25.

31. Daughters SB, Braun A, Sargeant BM, Reynolds EK, Hopko DR, Blanco C. Effectiveness of a brief behavioural treatment for inner city illicit drug users with elevated depressive symptoms. J Clin Psychiatry. 2008;69:122–9.

32. Darke S, Sims J, MacDonald S, Wickes W. Cognitive impairment among community setting. J Consult Clin Psychol. 2001;69:1007–17.

33. Matthews H, Kelly PJ, Deane FP. The dual diagnosis capability of residential treatment for alcohol and drug problems. London: Routledge; 2007. p. 319–39.

34. Morgenstern J, Blanchard KA, Morgan TJ, Labouvie E, Hayaki J. Testing the effectiveness of cognitive-behavioral treatment for substance abuse in a community setting. J Consult Clin Psychol. 2001;69:1007–17.

35. Matthews H, Kelly PJ, Deane FP. The dual diagnosis capability of residential treatment for alcohol and drug problems. London: Routledge; 2007. p. 319–39.

36. Hides L, Samet S, Lubman DI. Cognitive behaviour therapy (CBT) for the treatment of co-occurring depression and substance use: current evidence and directions for future research. Drug Alcohol Rev. 2010;29:518–7.

37. Hall SM, Muñoz RF, Reus VI. Cognitive-behavioural intervention increases abstinence rates for depressive-history smokers. J Consult Clin Psychol. 1994;62:141–6.

38. Brown RA, Evans DW, Miller IW, Burgess ES, Mueller TI. Cognitive-behavioral treatment for depression in alcoholism. J Consult Clin Psychol. 1997;65:715–25.

39. Lejuez C, Hopko DR, Acierno R, Daughters SB, Pagoto SL. Ten year revision of the brief behavioral activation treatment for depression: revised treatment manual. Behav Modif. 2011;35:111–61.

40. Hopko D, Lejuez C, Lepage J, Hopko S, Mcnelt D. A brief behavioral activation treatment for depression: A randomised pilot trial within an inpatient psychiatric hospital. Behav Modif. 2003;27:458–69.

41. Macptherson L, Tull MT, Matusiewicz AK, Rodman S, Strong DR, Kahler CW, et al. Randomized controlled trial of behavioral activation smoking cessation treatment for smokers with elevated depressive symptoms. J Consult Clin Psychol. 2010;78(1):55–61.

42. Saghafi M. MinimyPy Program. 2011: http://minimyPy.sourceforge.net. Accessed 6 Aug 2013.

43. Beck AT, Steer RA, Brown BK. Beck depression inventory manual. 2nd ed. San Antonio: Psychological Corporation; 1996.

44. Pocock SJ, Simon R. Sequential Treatment Assignment With Balancing for Prognostic Factors in the Controlled Clinical Trial Biometrics. 1975;31:103–15.

45. Smith RL. Sequential treatment allocation using biased-coin designs. J R Stat Soc Ser B Methodol. 1984;46:519–43.

46. Kolff P, Tooze JA, Talbot S, Covans D, Bevan DH, Treasure T. Pre-operative aspin decreases platelet aggregation and increases post-operative blood loss—a prospective, randomised, placebo controlled, double-blind clinical trial in 100 patients with chronic stable angina. Eur J Cardiothor Surg. 1994;404:9.

47. Hinze J. Power Analysis & Sample Size Software (PASS 2008). Kaysville: NCSS, LLC; 2008.

48. Kessler RC, Ustun TB. The world mental health (WMH) survey initiative version of the world health organization (WHO) composite international diagnostic interview (CIDI). Int J Methods Psychiatr Res. 2004;13:99–121.

49. Slade T, Sundemand M. Quantifying point prevalence of major depressive episode using lifetime structured diagnostic interviews. J Affect Disord. 2010;121:39–44.

50. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Intern Med. 2001;16:606–13.

51. Deady M, Ross J, Darke S. Suicide assessment Kit (SAK): a comprehensive assessment and policy development package. Sydney: National Drug and Alcohol Research Centre; 2015.

52. Darke S, Ross J, Mills KL, Williamson A, Havard A, Teesson M. Patterns of sustained heroin abstinence amongst long-term, dependent heroin users: 36 months findings from the Australian treatment outcome study (ATOS). Addict Behav. 2007;32:1897–906.

53. Wang YP, Gorenstein C. Psychometric properties of the Beck Depression Inventory II. A comprehensive review. Rev Bras Psiquiatr. 2013;35:416–31.

54. Haro J, Arababzadeh-Bouchez S, Brugha T, de Girolamo G, Guyer M, Lepine JP, Nazafi F, Rennes B, Villagut G, Sampson NA, Kessler RC. Concordance of the composite international diagnostic interview version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO world mental health surveys. Int J Methods Psychiatr Res. 2006:15:167–80.

55. Gosso M, Darke S, Griffiths P, Hando J, Powis B, Hall W, Sarah J. The Severity of Dependence Scale (SDS)—Psychometric Properties of the SDS in English and Austrian Samples of Heroin, Cocaine and Amphetamine Users. Addiction. 1995;90:607–14.

56. Erving JA. Detecting alcoholism. The CAGE questionnaire. JAMA. 1965;2:1905–7.

57. Dhall S, Kopeck JA. The CAGE questionnaire for alcohol misuse: A review of reliability and validity studies. Clin Invest Med. 2007;30:32–41.

58. Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Eval Program Plann. 1979:2:197–200.

59. Baker A, Kay-Lambkin F, Lee NK, Claire M, Jenner L. A Brief Cognitive Behavioural Intervention for Regular Amphetamine Users. Canberra: Australian Government Department of Health and Ageing; 2003.
66. Ross J, Tresson M, Darke S, Lynskey M, Ali R, Ritter A, Cooke R. The characteristics of heroin users entering treatment: Findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005;24:411–8.

67. Nunes EV, Hennessy G, Selzer J. Depression in patients with substance use disorder. In: Nunes EV, Selzer J, Levounis P, Davies CA, editors. Substance dependence and co-occurring psychiatric disorders. Best practices for diagnosis and clinical management. Kingston: Civic Research Institute; 2010. p. 1–20.

68. Magdison JP, Listhaus AR, Seitz-Brown CJ, Anderson KE, Lindberg B, Wilson A, et al. Rumination mediates the relationship between distress tolerance and depressive symptoms among substance users. Cognit Ther Res. 2013;37:456–65.

69. Cunningham R, Walton MA, Tripathi SP, Outman R, Murray R, Booth BM. Tracking inner city substance users from the ED: How many contacts does it take? Acad Emerg Med. 2008;15:136–43.

70. Manos RC, Kanter JW, Luo W. The behavioral activation for depression scale-short form: development and validation. Behav Ther. 2011;42:726–39.

71. Steer RA, Beck AT. Beck anxiety inventory. In: Zalaquett CP, Wood RJ, editors. Evaluating stress: A book of resources. Lanham: Scarecrow Education; 1997. p. 23–40.

72. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141–73.

73. Rytwinski NK, Liebowitz MR, Cissell S, Hofman SG. Screening for social anxiety disorder with the self-report version of the Liebowitz Social Anxiety Scale. Depression and Anxiety. 2009;26:34–8.

74. Weathers FW, Litz BT, Herman DS, Huska JA, Keane TM. The PTSD checklist (PCL): reliability, validity, and diagnostic utility. Annual convention of the international society for traumatic stress studies. San Antonio: ISTSS; 1993.

75. Loranger A. International Personality Disorder Examination (IPDE) manual. New York: Cornell Medical Centre; 1995.

76. Armento ME, Hopko DR. The environmental reward observation scale (EROS): development, validity, and reliability. Behav Ther. 2007;38:107–19.

77. Ehring T, Zetche U, Wiedacker K, Wahl K, Schönfeld S, Ehlers A. The perseverative thinking questionnaire (PTQ): validation of a content-independent measure of repetitive negative thinking. J Behav Ther Exp Psychiatry. 2011;42:225–32.

78. Ehring T, Raes F, Wiedacker K, Emmelkamp PMG. Validation of the perseverative thinking questionnaire—Dutch version (PTQ-NL). Eur J Psychol Assess. 2012;28:102–8.

79. Nolen-Hoeksema S, Morrow J. A prospective study of depression and post-traumatic stress symptoms after a natural disaster: The 1989 Loma Prieta earthquake. J Pers Soc Psychol. 1991;61:115–21.

80. Simons JS, Gaher RM. The distress tolerance scale: development and validation of a self-report measure. Motiv Emot. 2005;29:83–102.

81. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193–213.

82. Australian Bureau of Statistics. Technical manual: national survey of mental health and wellbeing, confidentialised unit record files, 2007. Canberra: Australian Bureau of Statistics; 2009.

83. Australian Institute of Health and Welfare. First report on national health priority areas 1996. Canberra: Australian Institute of Health and Welfare; 1997.